HSBC has maintained its buy call on Divi’s Laboratories Ltd with a target price of ₹7,400 per share, implying an upside potential of about 12% from the current market price of ₹6,607.00.
The brokerage said the company delivered a healthy Q2FY26 beat, primarily driven by the custom synthesis (CS) segment, which saw robust client demand. HSBC noted that the generics segment continued to face pricing pressure, but the strength in the CS business more than offset the impact.
The firm highlighted that Divi’s has established a strong Centre of Excellence in peptides, which is seeing rising client interest and higher order visibility. HSBC said a pickup in supplies for peptides and contrast media will be key to watch in the coming quarters.
The brokerage remains positive on Divi’s long-term outlook, backed by its leadership in custom synthesis, consistent execution, and a healthy pipeline of high-value APIs.
Disclaimer: The above article is based on brokerage reports and is for informational purposes only. It does not constitute investment advice or recommendations to buy or sell any securities.
